CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
Seo Yun Kim, Jae Kyung Myung, Hye-Ryoun Kim, Im Il Na, Jae Soo Koh, Hee Jong Baek, Cheol Hyeon Kim
Tuberc Respir Dis. 2019;82(1):62-70.   Published online June 19, 2018
DOI: https://doi.org/10.4046/trd.2018.0004

Excel Download

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
Tuberculosis and Respiratory Diseases. 2019;82(1):62   Crossref logo
Link1 Link2 Link3

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
OncoTargets and Therapy. 2016;355   Crossref logo
Link1

Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients
Lung Cancer. 2015;89(3):337-342   Crossref logo
Link1 Link2

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
OncoTargets and Therapy. 2021;Volume 13:13425-13435   Crossref logo
Link1 Link2

NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKI
Lung Cancer. 2013;82(1):177-178   Crossref logo
Link1 Link2

Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
Lung Cancer: Targets and Therapy. 2017;Volume 8:21-30   Crossref logo
Link1 Link2

Different first line EGFR-TKI regimen and the clearance of EGFR sensitive mutation in acquired EGFR-TKI resistant lung adenocarcinoma patients
Annals of Oncology. 2017;28:x130   Crossref logo
Link1 Link2 Link3

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Journal of Experimental & Clinical Cancer Research. 2012;31(1):   Crossref logo
Link1 Link2 Link3

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
OncoTargets and Therapy. 2017;Volume 10:447-452   Crossref logo
Link1 Link2

Squamous cell histological transformation beyond EGFR TKI treatment against EGFR-mutant lung adenocarcinoma
Annals of Oncology. 2015;26:vii138   Crossref logo
Link1 Link2 Link3